![TESAMORELIN [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/tesamorelin.jpg)
$80.00
Tesamorelin is a synthetic GHRH analog that stimulates the body’s own growth-hormone release. The approved prescription formulations are indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; they are not general weight-loss treatments. This 10 mg research vial is not the approved pharmaceutical product.
For laboratory research only. Not for human or animal consumption.
VIP Peptides · Research Compound
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH)
analog with an N-terminal modification intended to resist enzymatic
breakdown. It stimulates the pituitary to release endogenous growth
hormone and can raise IGF-1 levels. This profile covers a 10 mg
research vial.
Product Information
Tesamorelin stimulates the body’s own growth-hormone release in a
pulsatile pattern and can increase circulating IGF-1. It is not
exogenous growth hormone.
Tesamorelin is FDA-approved in specific prescription formulations
for reducing excess abdominal fat in adults with HIV-associated
lipodystrophy. That approval does not apply to a research-grade
10 mg vial, and the approved products have different strengths
and product-specific instructions.
| Product | Tesamorelin |
|---|---|
| Compound type | Synthetic GHRH analog |
| Research vial quantity | 10 mg |
| Research focus | Growth-hormone signaling and visceral fat |
| Approved prescription use |
Excess abdominal fat in adults with HIV-associated lipodystrophy |
| This research vial | Not an FDA-approved pharmaceutical product |
Evidence & Research
Clinical trials of approved tesamorelin formulations found
reductions in visceral adipose tissue in adults with
HIV-associated lipodystrophy. These results apply to the studied
prescription products and population.
Studies have also examined lipid measures and liver fat in related
populations. These findings do not expand the approved indication
or establish tesamorelin as a general weight-loss treatment.
Tesamorelin stimulates endogenous growth-hormone release and can
raise IGF-1. Hormone changes are not, by themselves, proof of
broader body-composition or performance benefits.
In clinical research, visceral-fat reductions may diminish after
treatment is stopped. Continued treatment and its risks require
assessment within the approved clinical context.
Evidence Limitations
Tesamorelin is not indicated for general weight loss or body
composition improvement in people without the approved condition.
Its long-term cardiovascular safety has not been established.
Approved EGRIFTA formulations and research-grade vials differ in
strength, diluent, preparation, storage and labeling. Instructions
for an approved product do not transfer to a research vial.
Safety & Regulatory Status
Possible adverse effects include injection-site reactions, fluid
retention, joint or muscle pain, and carpal-tunnel-like symptoms.
Tesamorelin can raise IGF-1 and may affect glucose tolerance; these
are important considerations for its approved prescription use.
Approved tesamorelin products have specific contraindications and
warnings, including pregnancy and active malignancy. Their prescribing
information calls for clinical assessment and monitoring.
FDA-approved tesamorelin formulations are indicated for reducing excess
abdominal fat in adults with HIV-associated lipodystrophy. They are not
indicated for general weight-loss management. A research-grade 10 mg
vial is not the approved prescription product.
Age & Policy Confirmation
Please confirm your age and review the policies before entering.
![TB500 Thymosin B4 [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/thy-300x300.jpg)
![Epitalon [50mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/epitalon-1-300x300.jpg)
Reviews
There are no reviews yet.